Regeneron

$450.01
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$5.41 (-1.18%) Today
-$3.18 (-0.70%) As of 12:51 PM UTC after-hours

Why Robinhood?

You can buy or sell Regeneron and other stocks, options, and ETFs commission-free!

About REGN

Regeneron Pharmaceuticals, Inc. Common Stock, also called Regeneron, is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY. The listed name for REGN is Regeneron Pharmaceuticals, Inc. Common Stock.

CEO
Leonard S. Schleifer
Employees
9,123
Headquarters
Tarrytown, New York
Founded
1988
Market Cap
49.55B
Price-Earnings Ratio
15.02
Dividend Yield
—
Average Volume
1.32M
High Today
$465.00
Low Today
$448.33
Open Price
$460.48
Volume
1.13M
52 Week High
$664.64
52 Week Low
$418.01

REGN News

Reuters1h

EU regulator endorses Regeneron antibody cocktail to treat COVID-19

Feb 26 (Reuters) - Europe's medicines regulator said on Friday that an antibody drug combination developed by Regeneron Pharmaceuticals can be used to treat COV
MarketWatch15h

Regeneron Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors

Shares of Regeneron Pharmaceuticals Inc. REGN, -1.18% slipped 1.18% to $453.19 Thursday, on what proved to be an all-around rough trading session for the stock
MarketWatch21h

Regeneron to share new data about COVID-19 antibody cocktail in March

Shares of Regeneron Pharmaceuticals Inc. REGN, -0.45% were up 0.2% in trading on Thursday after the company said an independent committee recommended the placeb

REGN Earnings

$0.00
$3.18
$6.35
$9.53
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 4, Pre-Market

You May Also Like

FNDB

More REGN News

ReutersFeb 20

Coronavirus-hit Czechs order Regeneron antibody drug ahead of EU registration

PRAGUE, Feb 20 (Reuters) - The Czech Republic, hard-hit bythe COVID-19 pandemic, has ordered 12,000 doses of an antibodytreatment made by Regeneron ahead of its
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure